Table 3.
Characteristics of responders vs. non-responders to rechallenge therapy at time of start of rechallenge therapy.
| No response to rechallenge therapy (n = 41) | Response to rechallenge therapy (n = 25) | |
|---|---|---|
| Age | ||
| Mean (SD) | 55.8 (14.5) | 65.1 (11.4) |
| Gender | ||
| Male | 23 (56.1%) | 16 (64.0%) |
| Female | 18 (43.9%) | 9 (36.0%) |
| ECOG PS | ||
| 0 | 15 (40.5%) | 10 (55.6%) |
| 1 | 20 (54.1%) | 8 (44.4%) |
| 2 | 2 (5.4%) | – |
| No. missings | 4 | 7 |
| LDH level | ||
| Normal | 21 (53.8%) | 14 (58.3%) |
| 1-2x elevated | 14 (35.9%) | 10 (41.7%) |
| >2x elevated | 4 (10.3%) | – |
| No. missings | 2 | 1 |
| Brain metastases | ||
| No | 16 (42.1%) | 11 (57.9%) |
| Yes | 22 (57.9%) | 8 (42.1%) |
| Symptomatic | 9 (23.7%) | 2 (10.5%) |
| Asymptomatic | 10 (26.3%) | 5 (26.3%) |
| Unknown if symptomatic | 3 (7.9%) | 1 (5.3%) |
| No. missings | 3 | 6 |
| Liver metastases | ||
| No | 29 (74.4%) | 19 (86.4%) |
| Yes | 10 (25.6%) | 3 (13.6%) |
| No. missings | 2 | 3 |
| BRAF V600 mutation | ||
| No | 7 (18.9%) | 9 (37.5%) |
| Yes | 30 (81.1%) | 15 (62.5%) |
| No. missings | 4 | 1 |
| Best response to initial treatment | ||
| CR | 4 (10.0%) | 3 (12.0%) |
| PR | 14 (35.0%) | 7 (28.0%) |
| SD | 6 (15.0%) | 8 (32.0%) |
| PD | 16 (40.0%) | 7 (28.0%) |
| No. missings | 1 | – |
| Initial treatment | ||
| Ipilimumab monotherapy | 18 (43.9%) | 12 (48.0%) |
| Ipilimumab + nivolumab | 23 (56.1%) | 13 (52.0%) |
| Toxicity grade ≥3 to initial therapy | ||
| No | 25 (62.5%) | 17 (68.0%) |
| Yes | 15 (37.5%) | 8 (32.0%) |
| No. missings | 1 | – |
| Reason for stopping initial therapy | ||
| Planned | 14 (35.9%) | 11 (44.0%) |
| Progression | 10 (25.6%) | 6 (24.0%) |
| Toxicity | 13 (33.3%) | 8 (32.0%) |
| Patient condition | 1 (2.6%) | – |
| Other | 1 (2.6%) | – |
| No. missings | 2 | – |
| Time between initial and rechallenge treatment | ||
| Median in months [Q1-Q3] | 22.8 [12.9–39.9] | 26.4 [11.6–58.8] |
| No. of therapy lines between treatments | ||
| Median [Q1-Q3] | 2 [1,2] | 1 [0-2] |